Accelalox Home Science Clinical Applications Company Careers Contact us


Dr. O’Connor’s research has identified the significant role played by arachidonic acid metabolites in regulating the bone formation process. His research is the basis for our program to develop small molecule therapies that will significantly accelerate fracture healing and spinal fusion. Peer-reviewed publications by Dr. O'Connor on this topic include:

Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing.
Cottrell JA, O'Connor JP.
J Bone Joint Surg Am. 2009 Nov;91(11):2653-65.PMID: 19884440

Accelerated fracture healing in mice lacking the 5-lipoxygenase gene.
Manigrasso MB, O'Connor JP.
Acta Orthop. 2010 Dec;81(6):748-55. Epub 2010 Nov 11.PMID: 21067431

Impact of analgesia on bone fracture healing.
Gerner P, O'Connor JP.
Anesthesiology. 2008 Mar;108(3):349-50. No abstract available. PMID: 18292668

Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing.
Simon AM, O'Connor JP.
J Bone Joint Surg Am. 2007 Mar;89(3):500-11.PMID: 17332098

Cyclo-oxygenase 2 function is essential for bone fracture healing.
Simon AM, Manigrasso MB, O'Connor JP.
J Bone Miner Res. 2002 Jun;17(6):963-76.PMID: 12054171

Intellectual Property

Accelalox has filed U.S. and international patent applications related to the use of its therapies to treat conditions requiring osteogenesis. U.S. Patent 7,829,535 was granted on November 9, 2010.